SEC Filing Summary
Issuer and period: The filing itself is Rexahn Pharmaceuticals, Inc.’s Form 10-K for the fiscal year ended December 31, 2011, filed March 15, 2012. The request metadata names Opus Genetics, which does not match the registrant identified in the filing; confirm the intended issuer before relying on this summary. This is an annual report, not a standalone Q4 filing.
Business context and reporting period
Rexahn described itself as a development-stage biopharmaceutical company developing cancer, CNS and sexual-dysfunction drug candidates. It had no product sales. Archexin was in Phase II testing for pancreatic cancer; Serdaxin and Zoraxel were clinical-stage CNS candidates, with further development decisions pending; other oncology compounds remained preclinical.
Financial performance and liquidity
| Metric | FY 2011 | FY 2010 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $16.13 million | $10.31 million |
| Research and development expense | $11.99 million | $3.93 million |
| General and administrative expense | $3.55 million | $5.99 million |
| Net loss | $11.34 million | $14.02 million |
| Basic and diluted loss per share | $0.12 | $0.18 |
| Cash used in operating activities | $15.53 million | $6.99 million |
FY 2011 net loss improved despite higher operating expenses, largely reflecting a $4.78 million noncash gain from revaluing warrant liabilities, compared with a $3.82 million noncash loss in 2010. Fourth-quarter 2011 reported net income was $389,281; the filing’s quarterly table also shows substantial other income in that quarter, so the result should not be read as evidence of product profitability.
At year-end, cash and cash equivalents were $9.86 million, marketable securities $1.95 million and restricted cash equivalents $1.43 million; the company reported these categories together as $13.24 million. Total assets were $13.69 million, total liabilities $2.98 million and stockholders’ equity $10.71 million. The filing reported no debt instruments on the balance sheet. Operating cash outflow was partly offset by $13.60 million of financing cash inflow, including equity issuances.
Material changes and developments
- R&D expense rose by $8.06 million, primarily due to approximately $7.43 million of Serdaxin Phase IIb trial costs and increased preclinical spending.
- G&A expense fell by $2.44 million, mainly because investor-relations stock compensation of $2.11 million incurred in 2010 did not recur.
- Common shares outstanding increased from 84.16 million at year-end 2010 to 95.35 million at year-end 2011, reflecting equity financing and other share issuances.
- In March 2011, the company raised $10 million gross in an equity offering and issued warrants; Teva separately purchased $3.95 million of shares in January for RX-3117 development.
Outlook, commentary and risks
Management expected existing cash and investments to cover minimum planned operating needs for approximately 15 months, with resources focused on Archexin and the preclinical pipeline. The filing also says additional financing would be needed to fund the broader operating plan; without it, Rexahn might reduce or delay R&D. Management estimated approximately $4.3 million for preclinical development, $4.7 million for corporate expenses and $220,000 for facilities rent through 2012, in addition to stated trial close-out and development costs.
- Serdaxin’s 300-patient Phase IIb MDD trial did not show efficacy over placebo on the MADRS primary measure, although it was described as safe and well tolerated. No further MDD development resources were then allocated.
- Archexin pancreatic-cancer trial enrollment was complete; results were anticipated in Q3 2012. RX-5902 and RX-3117 were described as possible candidates for clinical studies in the first half of 2012 and Q1 2012, respectively.
- Management was evaluating how to proceed with Zoraxel’s Phase IIb study after the Serdaxin results; both candidates share an active ingredient.
- Key risks include continued losses and financing dependence, clinical-trial outcomes and delays, regulatory approval, reliance on third-party researchers and manufacturers, competition, and patent protection. The company also disclosed $10.54 million in uninsured cash balances.
The independent auditor issued an unqualified opinion on the financial statements; management and the auditor reported effective internal control over financial reporting as of December 31, 2011.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is for Rexahn Pharmaceuticals, Inc., not Opus Genetics, Inc.
- Review the assumptions behind the stated 15-month minimum-operations runway and the need for additional financing.
- Assess the noncash warrant revaluation’s effect on reported annual and quarterly earnings.
- Check subsequent disclosures on Archexin trial results and decisions regarding Serdaxin and Zoraxel.
- Verify restrictions on the $1.39 million of remaining Teva-related RX-3117 funds and the potential dilution from outstanding warrants and options.